Company news

Halozyme Therapeutics, Inc. news in 2022

Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Halozyme reports third quarter 2022 financial and operating results

November 7, 2022

Halozyme to Report Third Quarter 2022 Financial and Operating Results

October 24, 2022

Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference

August 31, 2022

Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028

August 14, 2022

Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2028

August 14, 2022

Halozyme reports second quarter 2022 financial and operating results

August 8, 2022

Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer

August 1, 2022

Halozyme to Report Second Quarter 2022 Financial and Operating Results

July 25, 2022

Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

June 7, 2022

Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy

June 6, 2022

Halozyme Completes Antares Pharma Acquisition

May 23, 2022

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

May 11, 2022

Halozyme Reports First Quarter 2022 Results

May 9, 2022

Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call

May 2, 2022

Halozyme commences tender offer for all outstanding shares of common stock of antares pharma

April 25, 2022

Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

April 12, 2022

Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology

March 23, 2022

Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis

March 21, 2022

Halozyme Appoints Moni Miyashita to Board of Directors

March 14, 2022

Halozyme reports fourth quarter 2021 and full year results

February 21, 2022

Halozyme to host fourth quarter and full year 2021 financial results webcast and conference call

February 8, 2022

Halozyme Appoints New Chief Financial Officer

February 1, 2022

Halozyme provides 2022 financial guidance and outlook

January 9, 2022

Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference

January 3, 2022

Calls in 2022

Decks in 2022